Cystamine / cysteamine rescue the dopaminergic system and show neurorestorative properties in an animal model of Parkinson ’ s disease

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Not labeled

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• [Parkinson's disease].

  2022cited by this paper
• Human ESC-Derived Dopamine Neurons Show Similar Preclinical Efficacy and Potency to Fetal Neurons when Grafted in a Rat Model of Parkinson’s Disease

  2014cited by this paper
• The Allen Brain Atlas

  2014cited by this paper
• A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit.

  2014cited by this paper
• Cystathionine γ-lyase deficiency mediates neurodegeneration in Huntington’s disease

  2014cited by this paper
• Rasagiline in Parkinson's disease: a review based on meta-analysis of clinical data.

  2013cited by this paper
• Cell Therapy for Parkinson's Disease: What Next?

  2013cited by this paper
• Hematopoietic MyD88-adaptor Protein Acts as a Natural Defense Mechanism for Cognitive Deficits in Alzheimer’s Disease

  2012cited by this paper
• Dissection and culture of mouse dopaminergic and striatal explants in three-dimensional collagen matrix assays.

  2012cited by this paper
• Emerging therapies for Parkinson's disease.

  2012cited by this paper
• Combined Beneficial Effect of Rasagiline on Motor Function and Depression in De Novo PD

  2012cited by this paper
• Immune surveillance in the central nervous system

  2012cited by this paper
• Caffeine for treatment of Parkinson disease

  2012cited by this paper
• High-fat diet exacerbates MPTP-induced dopaminergic degeneration in mice.

  2012influential reference
• Adjunctive therapy in Parkinson’s disease: the role of rasagiline

  2012cited by this paper
• Transgenic conversion of omega-6 into omega-3 fatty acids in a mouse model of Parkinson's disease

  2011influential reference
• Neuroinflammation is associated with changes in glial mGluR5 expression and the development of neonatal excitotoxic lesions

  2011influential reference
• The role of the MYD88-dependent pathway in MPTP-induced brain dopaminergic degeneration

  2011influential reference
• Potential of cystamine and cysteamine in the treatment of neurodegenerative diseases.

  2011cited by this paper
• Lmx1a and Lmx1b Function Cooperatively to Regulate Proliferation, Specification, and Differentiation of Midbrain Dopaminergic Progenitors

  2011cited by this paper
• A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes.

  2011cited by this paper
• Combining nitric oxide release with anti-inflammatory activity preserves nigrostriatal dopaminergic innervation and prevents motor impairment in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease

  2010cited by this paper
• Cystamine prevents MPTP-induced toxicity in young adult mice via the up-regulation of the brain-derived neurotrophic factor.

  2010influential reference
• Differentiation of mouse Neuro 2A cells into dopamine neurons.

  2010cited by this paper
• Cystamine metabolism and brain transport properties: clinical implications for neurodegenerative diseases

  2010influential reference
• Trials of neuroprotective therapies for Parkinson's disease: problems and limitations.

  2010cited by this paper
• Serotonergic Neurons Mediate Dyskinesia Side Effects in Parkinson’s Patients with Neural Transplants

  2010cited by this paper
• Long‐term outcome of early versus delayed rasagiline treatment in early Parkinson's disease

  2009cited by this paper
• Neuroinflammation in Parkinson’s Disease

  2009cited by this paper
• Cystamine attenuates the expressions of NOS- and TLR-associated molecules in the brain of NZB/W F1 mice.

  2009cited by this paper
• Differences between subacute and chronic MPTP mice models: investigation of dopaminergic neuronal degeneration and α‐synuclein inclusions

  2009cited by this paper
• Modulation of brain-derived neurotrophic factor as a potential neuroprotective mechanism of action of omega-3 fatty acids in a parkinsonian animal model.

  2009cited by this paper
• Stepping test in mice: a reliable approach in determining forelimb akinesia in MPTP-induced Parkinsonism.

  2009cited by this paper
• Regional‐specific regulation of BDNF and trkB correlates with nigral dopaminergic cell sprouting following unilateral nigrostriatal axotomy

  2008cited by this paper
• Characterization of the striatal 6-OHDA model of Parkinson's disease in wild type and α-synuclein-deleted mice

  2008cited by this paper
• Therapeutic attenuation of mitochondrial dysfunction and oxidative stress in neurotoxin models of Parkinson's disease.

  2008influential reference
• Beneficial effects of dietary omega‐3 polyunsaturated fatty acid on toxin‐induced neuronal degeneration in an animal model of Parkinson's disease

  2008cited by this paper
• Growth cone chemotaxis.

  2008cited by this paper
• Cystamine and cysteamine increase brain levels of BDNF in Huntington disease via HSJ1b and transglutaminase.

  2006influential reference
• Selective injury to dopaminergic neurons up-regulates GDNF in substantia nigra postnatal cell cultures: role of neuron-glia crosstalk.

  2006cited by this paper
• CYTE‐I‐HD: Phase I dose finding and tolerability study of cysteamine (Cystagon) in Huntington's disease

  2006influential reference
• Neuroprotection by rasagiline: a new therapeutic approach to Parkinson's disease?

  2006cited by this paper
• 6-Hydroxydopamine-induced Apoptosis Is Mediated via Extracellular Auto-oxidation and Caspase 3-dependent Activation of Protein Kinase Cδ*

  2006cited by this paper
• Selective degeneration and nuclear localization of mutant huntingtin in the YAC128 mouse model of Huntington disease.

  2005cited by this paper
• Cerebral PET imaging and histological evidence of transglutaminase inhibitor cystamine induced neuroprotection in transgenic R6/2 mouse model of Huntington's disease.

  2005cited by this paper
• Cystamine increases l‐cysteine levels in Huntington's disease transgenic mouse brain and in a PC12 model of polyglutamine aggregation

  2004influential reference
• Astrocyte influences on ischemic neuronal death.

  2004cited by this paper
• N-Propargyl-1 (R)-aminoindan, rasagiline, increases glial cell line-derived neurotrophic factor (GDNF) in neuroblastoma SH-SY5Y cells through activation of NF-κB transcription factor

  2004cited by this paper
• Neuroprotective effect of rasagiline in a rodent model of Parkinson's disease.

  2004influential reference
• Tissue transglutaminase-induced aggregation of α-synuclein: Implications for Lewy body formation in Parkinson's disease and dementia with Lewy bodies

  2003cited by this paper
• A double‐blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease

  2003cited by this paper
• A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study.

  2002cited by this paper
• Drug-induced rotation intensity in unilateral dopamine-depleted rats is not correlated with end point or qualitative measures of forelimb or hindlimb motor performance.

  2002cited by this paper
• Therapeutic Effects of Cystamine in a Murine Model of Huntington's Disease

  2002cited by this paper
• Evidence for a role for transglutaminase in Huntington's disease and the potential therapeutic implications.

  2002influential reference
• Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline

  2001cited by this paper
• Antiapoptotic Properties of Rasagiline, N‐Propargylamine‐1(R)‐aminoindan, and Its Optical (S)‐Isomer, TV1022

  2001cited by this paper
• Parkinsonian motor deficits are reflected by proportional A9/A10 dopamine neuron degeneration in the rat.

  2001cited by this paper
• A second independent pathway for development of mesencephalic dopaminergic neurons requires Lmx1b

  2000cited by this paper
• Production of nitric oxide by glial cells: Regulation and potential roles in the CNS

  2000cited by this paper
• Science, medicine, and the future: Parkinson's disease.

  1999cited by this paper
• Running increases cell proliferation and neurogenesis in the adult mouse dentate gyrus

  1999cited by this paper
• Rasagiline, a monoamine oxidase‐B inhibitor, protects NGF‐differentiated PC12 cells against oxygen‐glucose deprivation

  1999cited by this paper
• S-methylthio-cysteine and cystamine are potent stimulators of thiol production and glutathione synthesis.

  1997cited by this paper
• Effects of donor age and brain-derived neurotrophic factor on the survival of dopaminergic neurons and axonal growth in postnatal rat nigrostriatal cocultures.

  1996cited by this paper
• In vivo expression of inducible nitric oxide synthase in experimentally induced neurologic diseases.

  1993cited by this paper
• Induction of calcium-independent nitric oxide synthase activity in primary rat glial cultures.

  1992cited by this paper

• The inflammatory injury in the striatal microglia-dopaminergic-neuron crosstalk involved in Tourette syndrome development

  2023cites this paper
• Baicalein Exerts Anti-Neuroinflammatory Effects by Inhibiting the TLR4-ROS /NF-κB-NLRP3 Inflammasome

  2021cites this paper
• Cofactors and Coenzymes | Cysteamine

  2021cites this paper
• Crystal structure of human cysteamine dioxygenase provides a structural rationale for its function as an oxygen sensor

  2021cites this paper
• Characterization of the nonheme iron center of cysteamine dioxygenase and its interaction with substrates

  2020cites this paper
• A transcription factor glial cell missing (Gcm) in the freshwater crayfish Pacifastacus leniusculus.

  2020cites this paper
• Beneficial effects of cysteamine in Thy1-α-Syn mice and induced pluripotent stem cells with a SNCA gene triplication.

  2020cites this paper
• The protective effect of biochanin A against rotenone-induced neurotoxicity in mice involves enhancing of PI3K/Akt/mTOR signaling and beclin-1 production.

  2020cites this paper
• Cysteamine as a novel disease-modifying compound for Parkinson's disease: Over a decade of research supporting a clinical trial.

  2019cites this paper
• Progressively disrupted somatodendritic morphology in dopamine neurons in a mouse Parkinson's model

  2018cites this paper
• Cofactor Biogenesis in Cysteamine Dioxygenase: C-F Bond Cleavage with Genetically Incorporated Unnatural Tyrosine.

  2018cites this paper
• Cysteine, Glutathione, and Thiol Redox Balance in Astrocytes

  2017cites this paper
• Effets des acides gras polyinsaturés oméga-3 dans deux modèles murins de maladie de Parkinson

  2017cites this paper
• Mécanismes cellulaires et moléculaires régulés par SLITRK2 et SLITRK5 dans la formation des circuits dopaminergiques du mésencéphale

  2016cites this paper
• Partial neurorescue effects of DHA following a 6-OHDA lesion of the mouse dopaminergic system.

  2016cites this paper